4GENE offers its FLAVOR-ON-DEMAND technology platform of activatable flavor and fragrance glucosides to its Customers in the Cosmetics, Food and Industrial Application Market Segments. 4GENE is a biotech start-up company founded at the Professorship for Biotechnology of Natural Products led by Prof. Dr. Wilfried Schwab at the Technical University Munich. During the EXIST Funding Program 4GENE cooperated with Prof. Dr.-Ing. Ralf Takors, Head of the Institute for Biotechnical Engineering at the University of Stuttgart to provide the Proof-of-Concept for the production of flavor glucosides. Today the company has 6 Employees and operates from Offices in Freising and Stuttgart in Germany with its customers worldwide.
Abalos Therapeutics has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system’s power specifically against cancer cells. Through viral replication within cancer cells, Abalos’ arenavirus-based drug candidates are designed to awake precise innate and adaptive immune responses and activate all relevant immune cell types against primary tumors and metastases. Led by experienced biotech entrepreneurs and immunology pioneers, Abalos’ goal is to achieve a quantum leap in immuno-oncology.
adivo is a biotech company generating therapeutic antibodies for companion animals, addressing the medical needs in dogs, with an upside potential for a future in care for other species.
Antibody selection is based on a novel fully synthetic, dog-specific phage display library that allows de-novo identification of antibodies to select a drug candidate with optimal properties.
adivo is a spin-off from MorphoSys AG, a leading European biopharmaceutical company. The team transfers an in-depth expertise in discovery and development of human therapeutic antibodies to the veterinary market.
Ark-Biodiversity is a green high-tech company. The company makes species protection possible by using their many years of scientific know-how, the latest genomic methods and custom adapted big-data technologies. Ark develops a universal test, the "Universal Fingerprint of Life", with which any living being and its products can be identified and characterized. Therefore they use blockchain-based technology, which provides the information gained in a contract- and counterfeit-proof manner for market participant – all for the protection of species and to prevent illegal animal trade.
Modern therapeutic approaches face the challenge to combine efficacy, low undesired side effects and reasonable pricing. Therefore, drug substances become more and more complex, therapies become more personalized while overall life-cycle costs from drug discovery up to the manufacturing of the final therapeutic are on trial.
Peptides – or short proteins - represent a promising therapeutic class, and Belyntic’s PEC technology offers an innovative solution for their manufacturing. The linker-based approach enables parallel, efficient and highly selective purification and modification of chemically synthesized peptides. Belyntic offers kit products as well as cooperation projects and custom services for research institutions, custom peptide manufacturers as well as biotech and pharma companies.
CereGate is developing a Computer-Brain-Interface (“BCI”) platform that is already capable to successfully submit information into the human brain. The revolutionary software platform is clinically validated and allows for enhanced treatment of various neurological and psychiatric disorders. The CereGate platform is able to transmit information into the brain („Mind-Writing“), by utilizing state of the art neuromodulation technology. While focusing first on improving gait symptoms for Parkinson patients, CereGate aims to become a key enabling tech¬nology in the field of rehabilitation and (neuro)prosthetics.
denovoMATRIX develops and manufactures biomimetic coatings for the cultivation of human stem cells. Our focus is on enabling culture conditions for stem and primary cells closer to the natural conditions found in the body. Our products offer a biologically relevant solution, which is both chemically defined, and modular for adapting to specific applications. Our vision is to enable human biology in vitro, beginning with Life Science research and onwards to cell therapies of the future.
GWA Hygiene is committed to reducing the number of hospital infections. For this purpose, the company has developed NosoEx, a modern monitoring system for measuring hand hygiene. The IoT system can be seamlessly integrated into the infrastructure of the health facilities. For this purpose, the existing disinfectant dispensers are equipped with sensors. The software can then be used to see how the disinfection figures for each station, donor and occupational group are developing. Measures to improve the hygiene situation can then be initiated.
The Stralsund start-up was founded in 2015 and now has 21 employees. In addition to Maik Gronau and Tobias Gebhardt, Dirk Amtsberg, Marcel Walz and Daniel Neuendorf are among the founding partners.
The NosoEx system is currently being used by a double-digit number of customers in the DACH region.
The founders of Kumovis GmbH have set themselves the goal of enabling the additive production of plastic implants and are developing innovative 3D printers specifically for medical products. Kumovis focuses on the processing of high-performance polymers, which are already established in medical technology. With the Kumovis system these plastics can be processed individually, decentrally and with a high degree of design freedom. Through the integration of a unique air circuit including filter units, the technology enables a clean room environment within the build chamber. The contamination of the component with foreign particles can be avoided. As a result, the Kumovis printer can produce products such as implants cost-effectively and at the same time patient-individualized.
mediaire GmbH was founded in 2018 in Berlin by experienced MRT and AI experts in order to support radiologists with innovative software solutions for the automatic diagnosis of MRT images. mediaire's solutions can be fully integrated into the internal IT infrastructure of radiology centers to ensure a smooth workflow and the highest possible protection of sensitive patient data. The first product md.Brain, which can be used for early detection and follow-up of neurodegenerative diseases, is already certified as a medical device and is therefore available for immediate use. Among the co-founders are two medical physicists with expertise in MRI and CI (Dr. Andreas Lemke and Dr. Jörg Döpfert), as well as two experienced scientists and specialists in radiology (Prof. Dr. med. Henrik Michaely and Prof. Dr. med. Michael Fenchel).
neotiv is a spin-off of the Otto von Guericke University in the German city of Magdeburg in close collaboration with the Magdeburg site of the German Centre for Neurodegenerative Diseases (DZNE). neotiv incorporates the latest scientific findings from the fields of neuroscience and dementia research into mobile software that can be used on smartphones and tablets. Our work focuses on the development of a digital assistant that can monitor and aid users' memories and provide support for patients with dementia. neotiv is also designed to improve the early detection of Alzheimer's dementia and to facilitate efficacy monitoring for new therapies as they become available in the future. Biologically and anatomically valid and user-oriented measurements of specific memory functions, which can be carried out on a regular basis, form the core of the development of neotiv. The measurements focus on regions of the brain that are affected in the early stages of Alzheimer's disease. The vision behind neotiv is to (i) help reducing risk factors for cognitive decline by making lifestyle change simple and cognitive health measurable and (ii) to enable the innovative early detection of cognitive difficulties and dementia risk.
In order to successfully treat the infected patient, you have to recognize and diagnose most reliably the infecting microbe.
Noscendo changes the way infection causative microbes are identified. Through a paradigm shift we introduce by using proprietary algorithms and software harnessing next generation sequencing, we identify pathogens from cell free nucleic acids in patient samples and thereby aid intensive care clinicians in their daily task to find the right decisions, enabling a targeted and successful treatment in an actionable timeframe.
Purenum is a spin-off of the Fraunhofer-IFAM and develops biocompatible adhesives for medical use. As part of a BMBF project (GO-Bio 6 "mediNiK"), an adhesive was developed that can be used to glue together and remove previously ungrippable kidney stone fragments after lithotripsy. In addition to work on the certification of the kidney stone adhesive, Purenum is also developing adhesives for other medical indications.
RIMASYS offers prefractures specimen for educational purposes in the field of orthopedic surgery. The innovative MedTech company is setting new standards in surgical education and implant development through innovative education and validation with life-like fractured human specimen.
SciRhom GmbH is a therapeutic antibody company developing first-in-class antibodies against iRhom2, a key modulator of several major pro-inflammatory signaling pathways, including TNF-alpha signaling. Based on a decade of cutting-edge bench research and the completion of a challenging, yet ultimately successful antibody campaign, SciRhom is now in the unique position to pursue the development of monoclonal antibodies against iRhom2 for the treatment of major autoimmune diseases.
Tacalyx researches and develops therapeutics targeting TACAs (tumor-associated carbohydrate antigens). These strongly tumor-specific structures are synthesized by cancer cells and contribute significantly to its virulence and metastasis. The recent possibility of synthesizing these complex structures allows the production of specific antibodies for the treatment of currently unsatisfactorily treatable cancers.